144 related articles for article (PubMed ID: 38250137)
41. Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
Al-Ahmad M; Ali A; Khalaf M; Alterki A; Rodriguez-Bouza T
BMC Pulm Med; 2023 Jul; 23(1):266. PubMed ID: 37464395
[TBL] [Abstract][Full Text] [Related]
42. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
Canonica GW; Bourdin A; Peters AT; Desrosiers M; Bachert C; Weidinger S; Simpson EL; Daizadeh N; Chen Z; Kamat S; Khan AH; Chao J; Graham NMH; Laws E; Rossi AB; Ardeleanu M; Mannent LP; Amin N; Ortiz B; Deniz Y; Djandji M; Rowe PJ
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1515-1526. PubMed ID: 35259535
[TBL] [Abstract][Full Text] [Related]
43. Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps.
Gangl K; Liu DT; Bartosik T; Campion NJ; Vyskocil E; Mueller CA; Knerer B; Eckl-Dorna J; Schneider S
J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672965
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
45. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
[TBL] [Abstract][Full Text] [Related]
46. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
[TBL] [Abstract][Full Text] [Related]
47. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
Dharmarajan H; Falade O; Lee SE; Wang EW
Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
[TBL] [Abstract][Full Text] [Related]
48. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
49. Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps.
Kariyawasam HH; James LK; Gane SB
Drug Des Devel Ther; 2020; 14():1757-1769. PubMed ID: 32440101
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF; Nair P; Brusselle G; Maspero JF; Castro M; Sher L; Zhu H; Hamilton JD; Swanson BN; Khan A; Chao J; Staudinger H; Pirozzi G; Antoni C; Amin N; Ruddy M; Akinlade B; Graham NMH; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2475-2485. PubMed ID: 29782224
[TBL] [Abstract][Full Text] [Related]
51. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps.
Siddiqui S; Bachert C; Chaker AM; Han JK; Hellings PW; Peters AT; Heffler E; Kamat S; Zhang H; Nash S; Khan AH; De Prado Gomez L; Jacob-Nara JA; Rowe PJ; Deniz Y
ERJ Open Res; 2022 Oct; 8(4):. PubMed ID: 36451848
[TBL] [Abstract][Full Text] [Related]
52. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
Busse WW; Maspero JF; Lu Y; Corren J; Hanania NA; Chipps BE; Katelaris CH; FitzGerald JM; Quirce S; Ford LB; Rice MS; Kamat S; Khan AH; Jagerschmidt A; Harel S; Rowe P; Pirozzi G; Amin N; Ruddy M; Graham NMH; Teper A
Ann Allergy Asthma Immunol; 2020 Nov; 125(5):565-576.e1. PubMed ID: 32474156
[TBL] [Abstract][Full Text] [Related]
54. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Papadopoulos NG; Szefler SJ; Bacharier LB; Maspero JF; Domingo C; Fiocchi A; Lee JK; Daizadeh N; Lederer DJ; Hardin M; Gall R; Djandji M; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
Allergy; 2023 Aug; 78(8):2157-2167. PubMed ID: 37059696
[TBL] [Abstract][Full Text] [Related]
55. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.
Domingo C; Maspero JF; Castro M; Hanania NA; Ford LB; Halpin DMG; Jackson DJ; Daizadeh N; Djandji M; Mitchell CP; Crikelair N; Jacob-Nara JA; Deniz Y; Rowe PJ; Ortiz B
J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1835-1843. PubMed ID: 35398549
[TBL] [Abstract][Full Text] [Related]
56. Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab.
Paoletti G; Casini M; Malvezzi L; Pirola F; Russo E; Nappi E; Muci GQ; Montagna C; Messina MR; Ferri S; Racca F; Lamacchia D; Cataldo G; Puggioni F; De Virgilio A; Ferreli F; Mercante G; Spriano G; Canonica GW; Heffler E
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):457-463. PubMed ID: 38095494
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life.
Nettis E; Brussino L; Patella V; Bonzano L; Detoraki A; Di Leo E; Sirufo MM; Caruso C; Lodi Rizzini F; Conte M; Yacoub MR; Triggiani M; Ridolo E; Macchia L; Rolla G; Brancaccio R; De Paulis A; Spadaro G; Di Bona D; D'Uggento AM; Ginaldi L; Gaeta F; Nucera E; Jaubashi K; Villalta D; Dagna L; Ciotta D; Pucciarini F; Bagnasco D; Celi G; Chieco Bianchi F; Cosmi L; Costantino MT; Crivellaro MA; D'Alò S; Del Biondo P; Del Giacco S; Di Gioacchino M; Di Pietro L; Favero E; Gangemi S; Guarnieri G; Heffler E; Leto Barone MS; Lombardo C; Losa F; Matucci A; Minciullo PL; Parronchi P; Passalacqua G; Pucci S; Rossi O; Salvati L; Schiappoli M; Senna G; Vianello A; Vultaggio A; Baoran Y; Incorvaia C; Canonica GW
Clin Mol Allergy; 2022 May; 20(1):6. PubMed ID: 35590407
[TBL] [Abstract][Full Text] [Related]
58. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
Corren J; Jackson DJ; Casale TB; Borish L; Rabe KF; Busse WW; Maspero JF; Jackson DJ; Daizadeh N; Altincatal A; Radwan A; Khodzhayev A; Djandji M; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():249-260. PubMed ID: 36915284
[TBL] [Abstract][Full Text] [Related]
59. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
60. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
